

# Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.



Abstract ID:PD-027

Daniele Rossini<sup>1</sup>, Filippo Pagani<sup>2</sup>, Antonio Pellino<sup>3-4</sup>, Emanuela Dell'Aquila<sup>5</sup>, Nicole Liscia<sup>6</sup>, Maria Bensi<sup>7</sup>, Marco Maria Germani<sup>1</sup>, Gianluca Masi<sup>1</sup>, Roberto Moretto<sup>1</sup>, Daniele Santini<sup>5</sup>, Lisa Salvatore<sup>7</sup>, Mario Scartozzi<sup>6</sup>, Sara Lonardi<sup>3</sup>, Gemma Zucchelli<sup>1</sup>, Elena Ongaro<sup>8</sup>, Francesca Vannini<sup>1</sup>, Camilla Colombo<sup>1</sup>, Alfredo Falcone<sup>1</sup>, Filippo Pietrantonio<sup>2</sup>, Chiara Cremolini<sup>1</sup>

1. Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana 2. Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori 3. Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology, IOV - IRCCS; 4. Department of Surgery, Oncology and Gastroenterology, University of Padua 5. Department of Medical Oncology, Campus Bio-Medico - University of Rome 6. Medical Oncology Department, University Hospital, University of Cagliari 7. Fondazione Policlinico Universitario Agostino Gemelli - IRCCS 8. Dipartimento di Oncologia Clinica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.

## Study background and design

- Retrospective analyses and phase II studies suggest that readministering an anti-EGFR in advanced lines may be effective in mCRC patients who achieved benefit from a 1<sup>st</sup>-line anti-EGFR containing regimen.

Santini et al., Ann Oncol 2012  
Cremolini et al., Jama Oncol 2018

- The identification of clinical features associated with benefit from anti-EGFR re-treatment in patients experiencing PD during 1<sup>st</sup>-line anti-EGFR (rechallenge) or after its interruption (reintroduction), is a major clinical need.

### RECHALLENGE

Reproposal, after an intervening treatment, of the same therapy to which tumor has already proved to be resistant

≠

### REINTRODUCTION

Reproposal of a treatment that was interrupted when the disease had not progressed

## Patients and Methods

A real-life data-base including a total of 5530 patients treated at 6 institutions from December 2010 to October 2018 was queried.

Patients were:

- Retreated with anti-EGFRs, with
- RAS/BRAF* wild-type status on tissue samples
- Had received a 1<sup>st</sup>-line anti-EGFR-based treatment
- At least SD as best response,
- At least one further line of therapy before anti-EGFR re-treatment, were included.

The association with RECIST response (RR), PFS and OS was investigated for the following variables:

- 1<sup>st</sup> line Response Rate (PR or CR vs SD or PD)
- PFS during 1<sup>st</sup>-line;
- Time from the last anti-EGFR administration to 1<sup>st</sup>-line PD (i.e. reintroduction vs rechallenge);
- Reason for anti-EGFR discontinuation in 1<sup>st</sup>-line (PD vs. other);
- Number of anti-EGFR-free lines of therapy before re-treatment;
- Anti-EGFR free interval (time between the last anti-EGFR administration in 1<sup>st</sup>-line and the time of re-treatment);
- Primary tumor side;
- Time from the diagnosis of metastatic disease to re-treatment (≥ vs. < 18 months).

## Demographics and disease characteristics

Characteristic. % patients	N=86
Sex (M / F)	63 / 37
Median Age (range)	64 (20 - 82)
ECOG PS (0 / 1-2 / NA)	53 / 37 / 10
Synchronous Metastases (Y / N)	66 / 34
Prior Adjuvant CT (Y / N)	26 / 74
Primary Tumor Site (right / left / rectum)	23 / 64 / 13
Number Metastatic Sites (1 / >1 / NA)	27 / 72 / 1
Resected Primary (Y / N)	88 / 12
Rechallenge / Reintroduction	65 / 35
Median N° lines before re-tx (range)	1 (1 - 7)


## Clinical Outcomes

ORR	19.8 %
DCR	46.5 %
mPFS	3.8 mos
mOS	10.2 mos

## Results


Characteristics, % patients	N=86	RR OR [95% CI]	RR p	PFS HR [95% CI]	PFS p	OS HR [95% CI]	OS p
1° line Response Rate (CR-RP / SD-PD)	92 / 8	1.68 [0.19-15.0]	0.64	0.72 [0.29-1.75]	0.40	1.53 [0.75-3.09]	0.28
1° line PFS (≥ vs. < 12 months)	47 / 53	0.98 [0.33-2.86]	0.97	0.86 [0.53-1.43]	0.55	0.89 [0.57-1.40]	0.62
Time last anti-EGFR to 1° PD (Reintroduction/Rechallenge)	35 / 65	1.17 [0.38-3.62]	0.78	0.89 [0.56-1.39]	0.61	1.13 [0.70-1.84]	0.60
Reason for discontinuation (PD / Other)	65 / 35	0.66 [0.22-2.00]	0.46	1.31 [0.84-2.04]	0.23	0.99 [0.62-1.60]	0.99
N° anti-EGFR free lines before re-tx (1 / >1)	71 / 29	0.41 [0.13-1.27]	0.12	0.86 [0.53-1.43]	0.55	1.10 [0.67-1.80]	0.71
Anti-EGFR Free Interval (≥ vs. < 15 months)	50 / 50	3.42 [0.98-10.87]	0.061	0.94 [0.61-1.46]	0.79	0.860 [0.54-1.35]	0.50
Primary Tumor side (left / right)	23 / 77	0.69 [0.21-2.28]	0.54	0.79 [0.46-1.34]	0.33	0.50 [0.26-0.93]	0.0052
Time from diagnosis of mCRC to re-tx (≥ vs. < 18 months)	77 / 23	2.77 [0.57-13.41]	0.21	0.98 [0.58-1.64]	0.93	0.60 [0.32-1.13]	0.054

## Progression-Free Survival



N. at risk	0	5	10	15
Rechallenge	56	17	7	2
Reintroduction	30	12	3	0

## Overall Survival



N. at risk	0	10	20	30	40	50
Rechallenge	56	26	5	2	1	0
Reintroduction	30	13	3	0	0	0

## Conclusions

Clinical factors that are generally believed to affect the efficacy of anti-EGFR re-treatments are not confirmed in our series. Therefore, clinicians should not rely on those characteristics in their decision-making on anti-EGFR re-treatment, and adequate studies for implementing liquid biopsy in clinical practice are urgently needed.

danielrossini87@gmail.com